Skip to content
PepGen Logo

PepGen: Q2 Newsletter

July 18, 2023

PepGen has released their Q2 Newsletter, including an update for the Canadian Duchenne muscular dystrophy community regarding the CONNECT1-ED051 clinical trial:

In May, PepGen received clearance from Health Canada to begin a Phase 2 first-ever human clinical trial of PGN-EDO5, CONNECT1-EDO51.

  • CONNECT1-EDO51 is an open-label, multiple ascending dose (MAD) clinical trial of PGN-EDO51 in people with DMD amenable to an exon 51 skipping approach.
  • CONNECT1-EDO51 will assess dystrophin levels, exon skipping data and safety data following multiple doses of PGN-EDO51.
  • PepGen expects to begin dosing patients with PGN-EDO51 in the second half of 2023.

CONNECT2-EDO51, a multinational study of PGN-EDO51, is planned. Preclinical data for PGN-EDO51 and information about PepGen’s clinical program were presented at the American Academy of Neurology meeting.

Defeat Duchenne Canada held a webinar with PepGen regarding these updates, which can be viewed here: